Objectway Accelerates Its Growth Path Through an Investment From Cinven in Partnership With Its Founder Luigi Marciano and the Existing Management Team
7.8.2025 09:00:00 CEST | Business Wire | Press Release
Luigi Marciano, founder of Objectway, a leading provider of software and services to financial institutions across Europe, North America and the Middle East, along with Objectway’s management team and international private equity firm, Cinven, today announced an agreement under which Cinven will make a majority investment in Objectway. Luigi Marciano will remain a significant shareholder alongside Cinven, and continue in his role as CEO and Chair. He and his existing management team will continue to manage the business, and Cinven’s backing will provide strategic and financial support, including continued investment in technology innovation, as well as support for future organic growth and targeted M&A opportunities. Together, Luigi Marciano, his team and Cinven aim to expand Objectway’s market leadership while delivering consistently high value to clients. Financial terms of the investment are not disclosed.
Objectway is a leading digital end-to-end “Solution-as-a-Service” provider for wealth managers, banks and asset managers. Objectway provides customers with a mission-critical, modular, front-to-back office software and solutions platform, delivered through a flexible design based on scalable cloud infrastructure. Founded in 1990 and headquartered in Milan, Objectway supports more than 250 financial institutions across more than 16 countries. With offices across Europe and North America, Objectway combines mission-critical technology and services with deep domain expertise.
The wealth management ecosystem is exhibiting consistent growth and strong demand for investment in modern technology solutions from established providers, presenting opportunities to digitise the industry and capture market share. Industry trends include the need to transition from fragmented legacy systems to integrated end-to-end solutions that create efficiency in front-to-back office processes, serving clients consistently, across the value chain, geographies, and investor segments.
Cinven believes that Objectway is a compelling primary investment opportunity based on a number of attractive characteristics, including its:
- Well-established position in a structurally growing market: Outsourced technology and tech-enabled services spend across the wealth management, banking and asset management industries is expected to grow strongly, driven by increasing regulatory complexity, customer demand for digital solutions, and the continued focus of customers on protecting margins;
- Differentiated offering: Objectway has a differentiated end-to-end front, middle and back-office platform offering across a wide-spectrum of wealth management customer types. Objectway has consistently been selected by many of the world's wealth managers, private banks, asset managers and asset services as their digital wealth platform for its thoughtful and innovative product roadmap, which integrates client feedback, regulatory requirements, technological advancements, and evolving market dynamics;
- Attractive and resilient business model: Objectway has highly recurring revenues and earnings visibility and strong cash flow generation, driven by its blue-chip customer base and growing “Solution-as-a-Service” delivery model;
- Multiple further growth and value creation levers: With Cinven’s financial and strategic support, there are significant further growth opportunities for the business, including through organic growth, targeted M&A, and accelerated investment into the technology platform; and
- Strong founder-led management team: Opportunity to partner with a strong and experienced management team led by its founder, CEO and Chair, Luigi Marciano, for the next stage of the company’s growth.
This transaction represents the first investment from Cinven’s new mid-market strategy. The European mid-market is an investment space where Cinven has deep expertise and networks to draw on, particularly in areas aligned with the firm’s core geographic and sector strengths, including across technology and tech-enabled services, financial services and business services.
Luigi Marciano, CEO, Chair and founder of Objectway said:
"Partnering with Cinven marks an exciting new chapter for Objectway. Their investment is a strong endorsement of our business model, our leadership team, and our long-term growth plan. Together, we’re well-positioned to accelerate our expansion, further strengthen our market position, accelerate the enhancement of our platform, and continue delivering exceptional value to our customers and to the market."
Luigi Sbrozzi, Partner and Co-Head of the Strategic Funds at Cinven said:
“We believe that Cinven makes an excellent partner to help Luigi Marciano and the wider management team achieve their bold growth ambitions. Cinven has a wealth of experience in the financial services and technology sectors, and a successful track record of partnering with exceptional management teams to create market leading businesses by investing for growth, including through tech-led innovation and buy and build strategies. We’re thrilled to back such a strong founder and management team to grow Objectway as a clear category leader, and look forward to working together to accelerate growth, broaden capabilities, and support global expansion.”
Advisors to Objectway on the transaction included Houlihan Lokey as financial advisor and Deloitte for strategic consulting on the business plan, as well as financial, commercial, and technical due diligence. PwC advised on tax and legal due diligence. Giovannelli Associati acted as the legal advisor and Russo De Rosa Associati as the tax advisor.
Cinven was advised by Jefferies (M&A), Freshfields (Legal), PwC (Financial), Alix Partners (Technology & Operations), Oliver Wyman (Commercial) and Deloitte (Tax and Structuring).
The transaction is subject to regulatory approvals and other customary closing conditions.
About Objectway
For more than 30 years, Objectway has been building successful partnerships with banking, asset and wealth management firms to empower and scale their business with a broader societal objective: preserve capital and improve the financial wellbeing of their clients.
Objectway offers a leading as-a-service growth platform for banks, wealth & asset managers and their investors. The Objectway platform provides these financial institutions with superior scalability for greater performance to empower their entire value chain.
Objectway’s end-to-end solution design allows its customers to be serviced consistently within both a local and international setting, underpinned by 24-7 secure infrastructure.
As a global Top 100 FinTech provider (IDC FinTech Rankings), Objectway administers more than €1 trillion of assets and supports more than 100,000 investment professionals (financial advisers, private bankers, relationship managers) to manage more than €800 billion of asset under management for more than 5 million investors. FY 2024 revenue exceeded €120 million and clients include more than 250 leading banks, wealth managers, asset managers and insurers across Europe, the Middle East and Canada.
Objectway has a global organisation including more than 800 business and technology professionals, with operating offices in Italy, the UK, Belgium, Germany, Switzerland, France, Ireland, and Canada.
Objectway’s flexible solution design addresses global and regional organisation structures across jurisdictions. Scale generates scale through expansion across customers, geographies and along the value chain.
About Cinven
Cinven is a leading international private equity firm focused on building world-class global and European companies. Its funds invest in six key sectors: Business Services, Consumer, Financial Services, Healthcare, Industrials and Technology, Media and Telecommunications (TMT). Cinven has offices in London, New York, Frankfurt, Paris, Milan, Madrid, Guernsey and Luxembourg.
Cinven takes a responsible approach towards its portfolio companies, their employees, suppliers, local communities, the environment and society.
Cinven Limited is authorised and regulated by the Financial Conduct Authority. Cinven Fund Management S.à r.l. is authorised and regulated by the Commission de Surveillance du Secteur Financier.
In this press release ‘Cinven’ means, depending on the context, any of or collectively, Cinven Holdings Guernsey Limited, Cinven Partnership LLP, and their respective Associates (as defined in the Companies Act 2006) and/or funds managed or advised by any of the foregoing.
For additional information on Cinven please visit www.cinven.com and www.linkedin.com/company/cinven/.
COPYRIGHT © 2025 OBJECTWAY GROUP
View source version on businesswire.com: https://www.businesswire.com/news/home/20250801371668/en/
Contacts
Contact – Objectway
Chiara Giudici
Communication Manager
+39 393 8229579
chiara.giudici@objectway.com
objectway.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.objectway.c
om%2F&esheet=54301675&newsitemid=20250801371668&lan=en-US&anchor=objectway.com&i
ndex=3&md5=6067f29f27d04d6761b8b4a2fa533c62
Marketing Team (Objectway)
mktg@objectway.com
Contact – Cinven
Clare Bradshaw
Tel. +44 (0)7881 918 967
Email. clare.bradshaw@cinven.com
Alison Raymond
Tel. +44 (0)7826 856198
Email. alison.raymond@cinven.com
Brunswick Group (Advisers to Cinven)
Joanna Donne
Cinven@Brunswickgroup.com
Tel. +44 (0)7834 307 881
Email. jdonne@brunswickgroup.com
Max McGahan
Tel. +44 (0) 7834 502369
Email. mmcgahan@brunswickgroup.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom